GPSM2 and gastric cancer: Further analysis using the Kaplan–Meier plotter tool demonstrated that a high expression of GPSM2 is associated with low OS (p = 9 × 10−14), false-positive (FP) results (p = 7.9 × 10−10), and progression-free survival (PPS) (p = 2.7 × 10−10) in gastric cancer patients (Figure 5B).